CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CRISPR Therapeutics AG
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$50.04+0.79 (+1.60%)
Close on Oct 19, 2026
- Market cap
- $4.83B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Operating margin
-18933.6%+30361.9 pts over 5 years
Net margin
-16569.8%+31951.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -90.6% | +43.1% | +37.3% | +30.4% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -22.8% | -26.8% | -30.2% | |
| Return on assets | -9.2% | -24.1% | -25.8% | |
| Current ratio | 14.56 | 18.21 | 13.32 | |
| Capex to revenue | 58.4% | 2553.3% | 26.0% | |
| Diluted shares | 12M | 66M | 90M |
Where the cash went
Fiscal 2021 to 2025, five years combined
CRISPR Therapeutics generated $1.78B from operations and spent $131.18M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.78B
Used
$131.18M
Capital expenditure$131.18M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-16569.8%
×Asset turnover0.00×
×Equity multiplier1.17×
=Return on equity, FY2025-30.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -16569.8% | 0.00× | 1.17× | -30.2% |
| FY2024 | -981.5% | 0.02× | 1.17× | -19.2% |
| FY2023 | -41.4% | 0.17× | 1.19× | -8.2% |
| FY2022 | -54271.7% | 0.00× | 1.17× | -30.4% |
| FY2021 | 41.3% | 0.40× | 1.13× | 18.6% |
| FY2020 | -48520.9% | 0.00× | 1.11× | -26.8% |
| FY2019 | 23.1% | 0.37× | 1.17× | 10.0% |
| FY2018 | -5281.1% | 0.01× | 1.31× | -56.9% |
| FY2017 | -166.7% | 0.13× | 1.47× | -32.5% |
| FY2016 | -448.8% | 0.02× | 2.48× | -22.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$581.60M
- Cash generatingOperating cash flow above zero-$345.01M
- Return on assets improvedROA up on the prior year-16.4% → -25.9%
- Earnings backed by cashOperating cash flow above net income-$345.01M vs -$581.60M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose22.07 → 13.32
- No dilutionShare count did not rise84M → 90M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.02 → 0.00